Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03664024
Title Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)
Acronym KEYNOTE-782
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP | CAN

Facility Status City State Zip Country Details
University Of Colorado ( Site 0908) Aurora Colorado 80045 United States Details
Harry & Jeanette Weinberg Cancer Institute ( Site 0901) Baltimore Maryland 21237 United States Details
Henry Ford Health System ( Site 0903) Detroit Michigan 48202 United States Details
Kingston General Hospital ( Site 0800) Kingston Ontario K7L 2V7 Canada Details
CISSS de la Monteregie-Centre ( Site 0801) Greenfield Park Quebec J4V 2H1 Canada Details
Orszagos Koranyi TBC es Pulmonologiai Intezet ( Site 0400) Budapest 1121 Hungary Details
Petz Aladar Megyei Oktato Korhaz ( Site 0402) Gyor 9024 Hungary Details
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0401) Szolnok 5000 Hungary Details
Meir Medical Center ( Site 0501) Kfar-Saba 4428164 Israel Details
Chaim Sheba Medical Center ( Site 0500) Ramat Gan 5262000 Israel Details
Hospital Universitario Insular de Gran Canaria ( Site 0700) Las Palmas de Gran Canaria Gran Canaria 35001 Spain Details
Hospital Puerta de Hierro ( Site 0702) Majadahonda Madrid 28222 Spain Details
H.U. Vall de Hebron ( Site 0701) Barcelona 08035 Spain Details
Hospital General Universitario 12 de Octubre ( Site 0703) Madrid 28041 Spain Details
Hospital Universitario Central de Asturias ( Site 0704) Oviedo 33011 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field